Trikafta 100-50-75 MG/150 MG UU 84S
Ended Awarded
- Contract number
- SPE2DB25FZX93
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,755
Award facts
- Contract value 100% obligated
- $24,754.56 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $24,754.56 by the Defense Logistics Agency on September 11, 2025, for the supply of Trikafta 100-50-75 mg/150 mg pharmaceutical product. The contract represents a firm fixed-price delivery order with an ultimate completion date of September 12, 2025, and carries no set-aside designation. This award leverages DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the DLA under the SPE2DB program, a $499.999 billion vehicle through November 2026 that enables the agency to issue delivery orders for comprehensive pharmaceutical products supporting military health facilities nationwide.
As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group specializes in distributing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare sites. The company's robust contract portfolio with the DLA demonstrates consistent success in competing for federal procurement opportunities, with previous awards covering diverse pharmaceutical products ranging from specialty medications to injections and contraceptive devices. This particular delivery order for Trikafta, a cystic fibrosis treatment, exemplifies the company's role in delivering essential medications to support military medical operations and healthcare services worldwide.
Quick answers
Who was awarded contract SPE2DB25FZX93?
SPE2DB25FZX93 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 11, 2025.
How much is contract SPE2DB25FZX93 worth?
The government has obligated $24,755 on SPE2DB25FZX93.
Is contract SPE2DB25FZX93 an order under another contract?
Yes. SPE2DB25FZX93 is a delivery order under SPE2DB20D9135, an indefinite delivery contract.
Was contract SPE2DB25FZX93 competed?
The extent of competition for SPE2DB25FZX93 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award